Phase II Randomized Controlled Trial of an Epidermal Growth Factor Vaccine in Advanced Non–Small-Cell Lung Cancer

Vinageras, Elia Nenínger; Torre, Ana de la; Rodríguez, Marta Osorio; Ferrer, Mauricio Catalá; Bravo, Idania; Pino, Mario Mendoza del; Abreu, Daniel Abreu; Brooks, Soraida Acosta; Rives, Rolando; Carrillo, Concepción del Castillo; Dueñas, Marta González; Viada, Carmen; Verdecia, Beatriz García; Ramos, Tania Crombet; Marinello, Gisela González; Dávila, Antonio

doi:10.1200/jco.2007.11.5980

Cited by 177 publications

(133 citation statements)

References 20 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…In this small trial conducted by Neninger et al, patients were randomized to receive either vaccination plus BSC or BSC alone. The investigational vaccine was administered on days 1, 7, 14, 28 and monthly thereafter after administration of a priming dose of cyclophosphamide (200 mg/m 2 ) [57]. The measurement of EGF in patients' serum showed reduced EGF concentrations in those in the experimental arm, which indirectly confirmed that CIMAVax induced production of anti-EGF antibodies.…”

Section: Muc1 and L-blp25 (Tecemotide)mentioning

confidence: 84%

“…In addition, a statistically significant improvement in survival (11.7 vs 3.6 months; p = 0.002) was also seen for patients with EGF antibody titers ‡ 1:4000. No critical side effects occurred in this trial [57]. A larger Phase II/III (Malaysian trial) study was started but interrupted in 2011 due to poor enrollment [58].…”

Section: Muc1 and L-blp25 (Tecemotide)mentioning

confidence: 99%

See 1 more Smart Citation

Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?

Rolfo

Sortino

Smits

et al. 2014

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Immunotherapy has been studied for many years in lung cancer without significant results, making the majority of oncologists quite skeptical about its possible application for non-small cell lung cancer treatment. However, the recent knowledge about immune escape and subsequent 'cancer immunoediting' has yielded the development of new strategies of cancer immunotherapy, heralding a new era of lung cancer treatment. Cancer vaccines, including both whole-cell and peptide vaccines have been tested both in early and advanced stages of non-small cell lung cancer. New immunomodulatory agents, including anti-CTLA4, anti-PD1/PDL1 monoclonal antibodies, have been investigated as monotherapy in metastatic lung cancer. To date, these treatments have shown impressive results of efficacy and tolerability in early clinical trials, leading to testing in several large, randomized Phase III trials. As these results will be confirmed, these drugs will be available in the near future, offering new exciting therapeutic options for lung cancer treatment.

show abstract

Section: Muc1 and L-blp25 (Tecemotide)mentioning

confidence: 84%

Section: Muc1 and L-blp25 (Tecemotide)mentioning

confidence: 99%

Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?

Rolfo

Sortino

Smits

et al. 2014

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

show abstract

“…This vaccine is cytostatic and prevents EGF binding to its receptor through development of antibody-mediated immunity to EGF. In a randomized phase II study, patients with advanced NSCLC who received the EGF vaccine after first-line chemotherapy had a trend toward improved survival (6.5 m vs. 5.3 m, P ¼ 0.098); however this was not statistically significant (43). Subsequently, enrollment has been completed on a phase III study in the same disease setting with results awaited (30).…”

Section: Egfmentioning

confidence: 99%

New Strategies in Lung Cancer: Translating Immunotherapy into Clinical Practice

Forde

Kelly

Brahmer

2014

Clinical Cancer Research

View full text Add to dashboard Cite

Recent breakthroughs in translating the early development of immunomodulatory antibodies into the clinic, notably with the anti-cytotoxic T-lymphocyte antigen-4 antibody, ipilimumab, have led to durable benefits and prolonged survival for a subgroup of patients with advanced melanoma. Subsequent studies have shown that related immune checkpoint antibodies, specifically those targeting the programmed death-1 pathway, have activity in non-small cell lung cancer. Non-small cell lung cancer is the commonest cause of cancer death worldwide and this exciting avenue of clinical investigation carries with it great promise and new challenges. In this article, we discuss recent developments in lung cancer immunotherapy, reviewing recent findings from therapeutic vaccine studies and in particular we focus on the refinement of immunomodulation as a therapeutic strategy in this challenging disease.

show abstract

“…In a phase II study, 80 patients with stage IIIB or IV NSCLC were randomized to receive EGF vaccination or BSC [100]. As with L-BLP25, vaccination was primed with cyclophosphamide and the EGF vaccine given on days 1, 7, 14, and 28, and monthly thereafter.…”

Section: Clinical Experience With Antigen-independent Immunomodulatormentioning

confidence: 99%

Targeting the immune system for management of NSCLC: the revival?

Reck

Vansteenkiste

Brahmer

2013

Curr Respir Care Rep

View full text Add to dashboard Cite

Immunotherapy, based on increasing knowledge of the mechanisms of immune-mediated elimination of tumor cells, is a new approach to lung cancer therapy. This paper reviews clinical experience of two types of immunotherapy for lung cancer. In the first approach antigen-independent immunomodulatory therapy is used to target crucial immune checkpoints. This strategy includes use of ipilimumab-to block the interaction of cytotoxic T-lymphocyte antigen-4 with CD80 and/or CD86, thereby enhancing T-cell proliferation-and the fully human monoclonal antibodies BMS-936558 and BMS-936559-to target the programmed cell death protein 1 signaling pathway, thereby enhancing T-cell proliferation, cytokine secretion, and cytolysis of target cells. The second approach is antigen-specific cancer immunotherapy, including vaccines against melanoma-associated antigen 3, mucinous glycoprotein-1, transforming growth factor-beta 2, epidermal growth factor, and, less specifically, whole-tumor cell extracts. An overview of the clinical data from these strategies is presented, with discussion of questions and issues that remain unanswered.

show abstract

Phase II Randomized Controlled Trial of an Epidermal Growth Factor Vaccine in Advanced Non–Small-Cell Lung Cancer

Cited by 177 publications

References 20 publications

Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?

Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?

New Strategies in Lung Cancer: Translating Immunotherapy into Clinical Practice

Targeting the immune system for management of NSCLC: the revival?

Contact Info

Product

Resources

About